摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4'-((4-(((3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyl)oxy)methyl)piperidin-1-yl)methyl)[1,1'-biphenyl]-2-carboxylic acid

中文名称
——
中文别名
——
英文名称
4'-((4-(((3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyl)oxy)methyl)piperidin-1-yl)methyl)[1,1'-biphenyl]-2-carboxylic acid
英文别名
2-[4-[[4-(3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyloxymethyl)piperidin-1-yl]methyl]phenyl]benzoic acid
4'-((4-(((3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyl)oxy)methyl)piperidin-1-yl)methyl)[1,1'-biphenyl]-2-carboxylic acid化学式
CAS
——
化学式
C32H32N2O5
mdl
——
分子量
524.616
InChiKey
MSRUMHDSLFSWRT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    39
  • 可旋转键数:
    8
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    81
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4'-((4-(((3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyl)oxy)methyl)piperidin-1-yl)methyl)[1,1'-biphenyl]-2-carboxylic acidcaesium carbonate 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 13.0h, 生成 (1-((2'-((acetoxymethoxy)carbonyl)[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate methanesulfonate
    参考文献:
    名称:
    Acidic biphenyl derivatives: Synthesis and biological activity of a new series of potent 5-HT4 receptor antagonists
    摘要:
    Serotonin (5-hydroxytryptamine, 5-HT) is an important signaling molecule in the central nervous system (CNS) and in non-neuronal tissues and organs. Serotonin mediates a positive chronotropic and inotropic response through 5-HT4 receptors in the atrium and ventricle of the heart. Recent investigations have revealed increased expression of the 5-HT4(b) isoform in cardiomyocytes of chronic arrhythmic and failing hearts, and that the use of 5-HT4 receptor antagonists may be beneficial for treating these conditions. The 5-HT4 receptor possesses a transmembrane (TM) binding site important for ligand affinity and recognition, as well as a capacity to accommodate bulky ligands. A new series of peripherally-acting 5-HT4 receptor antagonists were prepared by combining the acidic biphenyl group from the class of angiotensin II receptor blockers (ARBs) with the SB207266 (piboserod) scaffold. The new compounds were pharmacologically evaluated and carboxylic acid 21 was identified as a potent and promising 5-HT4 receptor antagonist with moderate affinity for the AT(1) receptor. The permeability of carboxylic acid 21 in a Caco-2 assay was low and the corresponding prodrug esters 23a-f were therefore prepared. The pharmacokinetics of methyl ester 20 and n-butyl ester 23c were evaluated in a rat model, revealing incomplete metabolism to carboxylic acid 21. However, methyl ester 20 is a potent 5-HT4 receptor antagonist with binding affinities in the low picomolar range. Methyl ester 20 has promising oral bioavailability and pharmacokinetics and may target 5-HT4 receptors in both CNS and peripheral organs. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2013.09.004
  • 作为产物:
    描述:
    4-piperidinylmethyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate 在 potassium carbonate 、 sodium hydroxide 作用下, 以 甲醇乙腈 为溶剂, 反应 36.0h, 生成 4'-((4-(((3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyl)oxy)methyl)piperidin-1-yl)methyl)[1,1'-biphenyl]-2-carboxylic acid
    参考文献:
    名称:
    Acidic biphenyl derivatives: Synthesis and biological activity of a new series of potent 5-HT4 receptor antagonists
    摘要:
    Serotonin (5-hydroxytryptamine, 5-HT) is an important signaling molecule in the central nervous system (CNS) and in non-neuronal tissues and organs. Serotonin mediates a positive chronotropic and inotropic response through 5-HT4 receptors in the atrium and ventricle of the heart. Recent investigations have revealed increased expression of the 5-HT4(b) isoform in cardiomyocytes of chronic arrhythmic and failing hearts, and that the use of 5-HT4 receptor antagonists may be beneficial for treating these conditions. The 5-HT4 receptor possesses a transmembrane (TM) binding site important for ligand affinity and recognition, as well as a capacity to accommodate bulky ligands. A new series of peripherally-acting 5-HT4 receptor antagonists were prepared by combining the acidic biphenyl group from the class of angiotensin II receptor blockers (ARBs) with the SB207266 (piboserod) scaffold. The new compounds were pharmacologically evaluated and carboxylic acid 21 was identified as a potent and promising 5-HT4 receptor antagonist with moderate affinity for the AT(1) receptor. The permeability of carboxylic acid 21 in a Caco-2 assay was low and the corresponding prodrug esters 23a-f were therefore prepared. The pharmacokinetics of methyl ester 20 and n-butyl ester 23c were evaluated in a rat model, revealing incomplete metabolism to carboxylic acid 21. However, methyl ester 20 is a potent 5-HT4 receptor antagonist with binding affinities in the low picomolar range. Methyl ester 20 has promising oral bioavailability and pharmacokinetics and may target 5-HT4 receptors in both CNS and peripheral organs. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2013.09.004
点击查看最新优质反应信息

文献信息

  • 5-HT RECEPTOR MODULATING COMPOUNDS
    申请人:Klaveness Jo
    公开号:US20120094989A1
    公开(公告)日:2012-04-19
    The present invention relates to compounds having 5-hydroxytryptamine receptor modulating activity, in particular compounds having an acidic moiety held distant from the 5-HT pharmacophore by a rigid linker group, to compositions containing such compounds and methods of treatment using them. Such compounds have an increased affinity for the 5-HT receptor and a reduced hERG effect. Certain compounds of the invention further exhibit an angiotensin II receptor modulating activity. Claimed are compounds of formula (I): HT-L-A. HT is a 5-HT receptor modulating moiety containing a basic nitrogen atom; A is an acid moiety; L is a linker moiety.
    本发明涉及具有5-羟色胺受体调节活性的化合物,特别是具有酸性基团,由刚性连接基团将其与5-HT药效团分开的化合物,以及含有这些化合物的组合物和使用它们的治疗方法。这些化合物具有对5-HT受体的增强亲和力和减少hERG效应。本发明的某些化合物还表现出血管紧张素II受体调节活性。本发明要求的是式(I)的化合物:HT-L-A。其中,HT是包含碱性氮原子的5-HT受体调节基团;A是酸性基团;L是连接基团。
  • [EN] 5-HT RECEPTOR MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULATEURS DU RÉCEPTEUR 5-HT
    申请人:SERODUS AS
    公开号:WO2010112865A1
    公开(公告)日:2010-10-07
    The present invention relates to compounds having 5-hydroxytryptamine receptor modulating activity, in particular compounds having an acidic moiety held distant from the 5-HT pharmacophore by a rigid linker group, to compositions containing such compounds and methods of treatment using them. Such compounds have an increased affinity for the 5-HT receptor and a reduced hERG effect. Certain compounds of the invention further exhibit an angiotensin II receptor modulating activity. Claimed are compounds of formula (I): HT - L - A. HT is a 5-HT receptor modulating moiety containing a basic nitrogen atom; A is an acid moiety; L is a linker moiety. Examples of particular preterred HT groups are: (a) (b). Examples of particular preferred L groups comprise formula ( Vl ) and (VII) moieties: Examples of acid moieties are: -C(O)OR I. -OP(O)(OR2)2, -P(O)(OR2)2, -SO2OR2, -S03H, -0S03H, -P(O)(OH )2.
  • Acidic biphenyl derivatives: Synthesis and biological activity of a new series of potent 5-HT4 receptor antagonists
    作者:Bjarne Brudeli、Kjetil Wessel Andressen、Lise Román Moltzau、Nils Olav Nilsen、Finn Olav Levy、Jo Klaveness
    DOI:10.1016/j.bmc.2013.09.004
    日期:2013.11
    Serotonin (5-hydroxytryptamine, 5-HT) is an important signaling molecule in the central nervous system (CNS) and in non-neuronal tissues and organs. Serotonin mediates a positive chronotropic and inotropic response through 5-HT4 receptors in the atrium and ventricle of the heart. Recent investigations have revealed increased expression of the 5-HT4(b) isoform in cardiomyocytes of chronic arrhythmic and failing hearts, and that the use of 5-HT4 receptor antagonists may be beneficial for treating these conditions. The 5-HT4 receptor possesses a transmembrane (TM) binding site important for ligand affinity and recognition, as well as a capacity to accommodate bulky ligands. A new series of peripherally-acting 5-HT4 receptor antagonists were prepared by combining the acidic biphenyl group from the class of angiotensin II receptor blockers (ARBs) with the SB207266 (piboserod) scaffold. The new compounds were pharmacologically evaluated and carboxylic acid 21 was identified as a potent and promising 5-HT4 receptor antagonist with moderate affinity for the AT(1) receptor. The permeability of carboxylic acid 21 in a Caco-2 assay was low and the corresponding prodrug esters 23a-f were therefore prepared. The pharmacokinetics of methyl ester 20 and n-butyl ester 23c were evaluated in a rat model, revealing incomplete metabolism to carboxylic acid 21. However, methyl ester 20 is a potent 5-HT4 receptor antagonist with binding affinities in the low picomolar range. Methyl ester 20 has promising oral bioavailability and pharmacokinetics and may target 5-HT4 receptors in both CNS and peripheral organs. (C) 2013 Elsevier Ltd. All rights reserved.
查看更多